10-Q: Sensus Healthcare Reports Sharp Revenue Drop, Increased Net Loss

Sensus Healthcare's Q2 2026 results show a significant 68.5% revenue decline and a widened net loss, impacted by reduced unit sales and a shift towards revenue recognition over time.

Summary

• Sensus Healthcare reported a substantial decrease in revenue for the second quarter of 2026, down 68.5% to $2.3 million from $7.3 million in the prior year period.
• The six-month period also saw a significant revenue decline of 63.7%, falling to $5.7 million from $15.7 million in the same period of 2025.
• Net loss for the three months ended June 30, 2026, was $8.7 million, a significant increase from $1.0 million in the prior year.
• The net loss for the six months ended June 30, 2026, was $11.4 million, compared to $3.6 million in the prior year.
• Gross profit margin decreased to 34.8% in Q2 2026 from 39.7% in Q2 2025, attributed to product mix and upfront costs for 'Fair Deal Agreements'.
• Operating expenses decreased across general and administrative, selling and marketing, and research and development categories.
• The company has a new revolving credit facility with CNB, but no borrowings were outstanding as of June 30, 2026.
• A valuation allowance was recorded against deferred tax assets, significantly impacting the effective tax rate.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative report due to a significant decline in revenue and a substantial increase in net loss, indicating a challenging operational period.

Positives

• Operating expenses in general and administrative, selling and marketing, and research and development all saw decreases compared to the prior year periods.
• The company has secured a new revolving credit facility with CNB, providing potential access to $15.0 million.
• Inventories increased, suggesting anticipation of future sales growth.

Negatives

• Revenue for the three months ended June 30, 2026, decreased by 68.5% to $2.3 million from $7.3 million in the prior year.
• Revenue for the six months ended June 30, 2026, decreased by 63.7% to $5.7 million from $15.7 million in the prior year.
• Net loss for the three months ended June 30, 2026, was $8.7 million, compared to $1.0 million in the prior year.
• Net loss for the six months ended June 30, 2026, was $11.4 million, compared to $3.6 million in the prior year.
• Gross profit margin decreased to 34.8% in Q2 2026 from 39.7% in Q2 2025.
• Accounts receivable decreased significantly by $4.3 million, primarily due to decreased sales.
• Cash, restricted cash, and cash equivalents decreased by $6.9 million, largely due to cash used to purchase inventory.

Risks

• Concentration of customers in the U.S. and China, with significant revenue from a few key customers.
• Geopolitical tensions between the U.S. and China could impact business.
• The company's ability to manage manufacturing processes and costs.
• Potential for new products or technologies to render current offerings obsolete.
• Reliance on government and third-party payor reimbursement for clinical procedures.
• Inflationary pressures may continue to impact sales.
• The company is unable to estimate the cost, if any, associated with the Department of Justice investigation.
• The CNB Credit Facility has restrictions on asset sales, incurring other indebtedness, and liens.

Future Outlook

The company believes that proceeds from maturing cash equivalents, as well as cash on hand, are sufficient to meet operating capital and funding requirements for the next 12 months. Management regularly evaluates cash requirements and may seek to raise additional funds in the future, but there is no assurance of success or favorable terms.

Management Comments

• Management concluded that a valuation allowance against the Company's net deferred tax assets was required, materially increasing income tax expense and the effective tax rate for the six-month period ended June 30, 2026.
• Management will continue to evaluate the realizability of its deferred tax assets each reporting period based on all available evidence.
• Management evaluated the effectiveness of disclosure controls and procedures and concluded they were effective as of June 30, 2026.
• There have been no significant changes in internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Industry Context

StockSavvy.ai notes that Sensus Healthcare operates in the medical device sector, specifically focusing on radiation therapy for skin conditions. The reported revenue decline and increased net loss suggest challenges in sales execution or market demand, potentially exacerbated by the company's customer concentration and the shift towards revenue recognition over time for certain service agreements.

Legal Proceedings

• The company received a Civil Investigative Demand from the Department of Justice regarding billing to Medicare by a physician using the company's SRT-100. The investigation is ongoing, and the company disputes any wrongdoing.

Stakeholder Impact

• Shareholders may be negatively impacted by the significant decline in revenue and increase in net loss, potentially affecting stock valuation.
• Customers may be affected by the company's focus on 'Fair Deal Agreements' and revenue recognition over time, potentially altering payment structures.
• Suppliers may experience changes in order volumes due to the decrease in unit sales.

Next Steps

• Continue to monitor the impact of inflation and take actions to minimize its effects.
• Management will continue to evaluate the realizability of deferred tax assets each reporting period.
• The company may seek to raise additional funds in the future for operational needs, capital requirements, and business development transactions.

Key Dates

Recommendation

The significant decline in revenue, widening net loss, and reduced gross margins indicate a deteriorating financial performance. While operating expenses have been reduced, the core business appears to be under considerable pressure, making it a sell recommendation until a clear turnaround strategy and execution are demonstrated.

Keywords

Sensus Healthcare, Form 10-Q, Quarterly Report, Radiation Therapy, SRT Technology, Medical Devices, Financial Results, Revenue Decline